*The UK incidence of anaphylactic reactions is increasing. *Patients who have an anaphylactic reaction have life-threatening airway and, or breathing and, or circulation problems usually associated with skin or mucosal changes. *Patients having an anaphylactic reaction should be treated using the Airway, Breathing, Circulation, Disability, Exposure (ABCDE) approach. *Anaphylactic reactions are not easy to study with randomised controlled trials. There are, however, systematic reviews of the available evidence and a wealth of clinical experience to help formulate guidelines. *The exact treatment will depend on the patient's location, the equipment and drugs available, and the skills of those treating the anaphylactic reaction. *Early treatment with intramuscular adrenaline is the treatment of choice for patients having an anaphylactic reaction. *Despite previous guidelines, there is still confusion about the indications, dose and route of adrenaline. *Intravenous adrenaline must only be used in certain specialist settings and only by those skilled and experienced in its use. *All those who are suspected of having had an anaphylactic reaction should be referred to a specialist in allergy. *Individuals who are at high risk of an anaphylactic reaction should carry an adrenaline auto-injector and receive training and support in its use. *There is a need for further research about the diagnosis, treatment and prevention of anaphylactic reactions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.resuscitation.2008.02.001 | DOI Listing |
Allergol Immunopathol (Madr)
January 2025
Department of Pediatrics, University Hospital of Ioannina, Ioannina, Greece.
Anaphylaxis, the most severe end of the spectrum of allergic reactions, has shown increasing incidence globally over recent years. This hypersensitivity reaction can occur at any age, including infancy. Recent data, although scarce, show that anaphylaxis is increasingly reported in infancy, with food identified as the leading cause of anaphylaxis cases in this age group.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
January 2025
Department of Allergy and Clinical Immunology, Firooz Abadi Hospital, Iran University of Medical Sciences, Tehran, Iran;
Background: Hymenoptera venom allergy is a potentially severe allergic reaction in the general population. The only preventative approach in these cases is venom immunotherapy (VIT), which follows different protocols. The recommended initial dose is 0.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
January 2025
Division of Allergy and Clinical Immunology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
This study aimed to characterize the profile of probable anaphylaxis cases treated at a private pediatric hospital emergency department in São Paulo. It investigated triggering factors, the presence of cofactors, treatments administered, and follow-up for these cases through interviews with the patients' families. A single-center cross-sectional study analyzed medical records of children and adolescents treated between 2016 and 2020.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
January 2025
Department of Research and Development, Inmunotek SL, Alcalá de Henares, Madrid, Spain.
Background: Anaphylaxis is a severe allergic reaction with increasing incidence in Europe. It is often caused by food, insect venom, and drugs. White, red, and green beans () are legumes of the family consumed worldwide.
View Article and Find Full Text PDFClin Exp Allergy
January 2025
Department of Health Sciences, University of Florence, Florence, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!